Mesupron, which targets gastrointestinal and other cancers, has been licensed from Wilex.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
RedHill Biopharma Ltd. (Nasdaq: RDHL); TASE: RDHL) has expanded its late clinical-stage gastrointestinal-focused pipeline by licensing Mesupron, an oncology drug targeting gastrointestinal and other solid tumor cancers, from Wilex AG.
Mesupron, a small molecule uPA inhibitor administered by oral capsule, presents a new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit both tumor metastasis and growth.
RedHill CEO Dror Ben-Asher said, “The acquisition of Mesupron reflects our commitment to patients suffering from gastrointestinal and inflammatory diseases, including related cancers such as pancreatic cancer, gastric cancer and colorectal cancer. It adds to RedHill’s pipeline of six late clinical-stage drug candidates and fits well with our risk-mitigating business model.”
Under the terms of the agreement, RedHill acquired the exclusive development and commercialization rights to Mesupron, excluding China, Hong Kong, Taiwan and Macao, for all indications. RedHill will pay WILEX an upfront payment of $1 million and potential royalties on net revenue of up to 30%. RedHill will be responsible for all development, regulatory and commercialization of Mesupron.